ANI Raises 2025 Guidance On Back Of Strong Results And Momentum
The Company’s Cortrophin Gel Continues To Display Strong Growth Potential
ANI’s generic division and rare disease business have both led to a boost in net revenue for the past quarter and in forecasts for the coming year.
